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CCSVI: Is Blinding the Key?
C.A. Mayer*, U. Ziemann
Department of Neurology, Goethe-University Frankfurt, Schleusenweg 2e16, 60528 Frankfurt am Main, GermanyWhen Zamboni et al. presented a new pathophysiological
hypothesis, proof of concept and possible cure for multiple sclerosis
(MS) in 2009,1e3 many were intrigued by the simplicity of the
‘chronic cerebrospinal venous insufﬁciency’ (CCSVI) hypothesis.
This concept transferred the known pathophysiology of chronic
venous insufﬁciency (CVI) from the leg to the brain, as Zamboni
et al. proposed that the formation of MS lesions in the brain was
a consequence of intracerebral erythrocyte extravasation due to
elevated transmural venous pressure, followed by erythrocyte
degradation and iron-driven phagocytosis.3
The ﬁrst open-label interventional study by Zamboni et al.2
aimed to explore the efﬁcacy and tolerability of transluminal
venoplasty (PTA) for the treatment of ‘CCSVI’ in 65 patients. It re-
ported a doubling of the rate of relapse-free patients in the RRMS-
group from 27% to 50%, a reduction in the rate of contrast-
enhancing lesions in MRI from 50% to 12% of patients and a signif-
icant improvement in the MSFC-score. These controversial ﬁndings
were, however, subjected to critical scrutiny because of crucial
shortcomings in trial design.4e6
Three major omissions cast doubt on the validity of these data2:
First: no blinding was applied to either the ultrasonographer who
assessed post-interventional vascular outcome measures or the
evaluating physician who assessed EDSS-, MSFC- and QOL- scores,
despite the recognized susceptibility of these assessments to rater
bias. Second: no sham interventionwasperformed to exclude placebo
effects, while third; no information was provided as to whether
venoplasty patients were prescribed (or were already taking) any
other disease modifying medications at the time of their procedure.
In this issue of the EJVES,1 Zamboni et al. present the results of
another interventional study, where they applied PTA to 15 ‘CCSVI-
positive’ MS patients. The group was divided into an ‘immediate
treatment group’ (ITG) and a ‘delayed treatment group’ (DTG:
where PTA was performed after a delay of 6 months). The trial
yielded apparently corroborative data, in particular a relapse rate
reduction of 80% at 1 year follow-up in the ITG group. In this paper,
Zamboni et al. state that their preceding study had been ‘criticized
because of the lack of a control group and blinded, objective MRI
measurements’.1 Given the methodological shortcomings of his
earlier study, the reader would surely then expect the authors to
have met basic scientiﬁc requirements in their latest study. In the
introduction to their paper, Zamboni et al. reﬂected on these* Corresponding author.
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these criticisms and to determine whether treatment of CCSVI with PTA
affected disease progression in patients with MS’.1
However, a careful review of the methodology of the new study
still raises the question as to what extent these demands were
satisﬁed, given that no speciﬁc information concerning blinding
precautions were provided. First, Zamboni et al. failed to inform the
reader how clinical and MRI assessors of the post-interventional
outcome were blinded toward the ITG/DTG group assignment of
the patients. The failure to ensure safe exclusion of assessor bias is
a fundamental methodological failure, which gives rise to
substantial doubts regarding the validity of the new data. Second, in
the absence of a sham-procedure, the patients included in this trial
were aware of their intervention and therefore susceptible to well
recognized placebo effects.
Accordingly, the added value of this study for assessing the
therapeutic effect of PTA in MS must be regarded as minimal in
absolute terms. Data which are obtained whilst ignoring the
importance of assessor bias and placebo effects should not serve as
supportive evidence for the efﬁcacy of endovascular treatment in
MS. As we have learned from preceding publications,5,6,7 ‘truth’ in
the CCSVI hypothesis is crucially dependent on the awareness of
both the evaluating physician and the evaluated patient. Therefore,
independent, randomized double-blinded trials (including sham
intervention) are warranted in order to obtain valid and reliable
data to prove or refute this therapeutic algorithm for MS.
As a consequence of these methodological and ethical concerns,
practice statements (like those recently published by the EFNS- and
ENS Multiple Sclerosis Scientist Panel and ECTRIMS Executive
Committee8) are essential, given the prominence accorded to lay
discussions regarding the CCSVI hypothesis in the print media,
internet blogs and social networks. A lack of scientiﬁc evidence has
been substituted by emotional testimonials from treated patients,
leading to the development of a lucrative industry of dubious
‘CCSVI-centres’9,10 who are eager to respond to patient demands by
offering them ‘liberation’ (according to Zamboni) at costs ranging
from $640010 to $980011,12 but without any serious or independent
corroborative scientiﬁc evidence.10
The consequence of this unprecedented, erratic development in
modernmedicine presents the medical community with a two-fold
challenge; namely that of maintaining scientiﬁc rigor regarding the
performance and interpretation of CCSVI trials and then the ethics
of translating the results of these trials into treatment recom-
mendations. Given the absence of proven therapeutic beneﬁts andd by Elsevier Ltd. All rights reserved.
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ment of ‘CCSVI’,13,14 interventional treatment of ‘CCSVI’ outside
standardized clinical trials is unethical and must be strongly
discouraged. If such clinical trials are to be performed, they must
adhere to the basic standards of a double-blind randomized, sham
controlled study.References
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